KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBT Margin (2017 - 2025)

Sarepta Therapeutics has reported EBT Margin over the past 12 years, most recently at 80.69% for Q4 2025.

  • Quarterly results put EBT Margin at 80.69% for Q4 2025, up 5461.0% from a year ago — trailing twelve months through Dec 2025 was 3.03% (down 1674.0% YoY), and the annual figure for FY2025 was 3.03%, down 1674.0%.
  • EBT Margin for Q4 2025 was 80.69% at Sarepta Therapeutics, up from 48.59% in the prior quarter.
  • Over the last five years, EBT Margin for SRPT hit a ceiling of 123.81% in Q4 2021 and a floor of 2329.97% in Q1 2023.
  • Median EBT Margin over the past 5 years was 18.01% (2023), compared with a mean of 229.19%.
  • Biggest five-year swings in EBT Margin: crashed -228057bps in 2023 and later surged 234000bps in 2024.
  • Sarepta Therapeutics' EBT Margin stood at 123.81% in 2021, then plummeted by -84bps to 19.31% in 2022, then skyrocketed by 55bps to 29.85% in 2023, then dropped by -13bps to 26.08% in 2024, then surged by 209bps to 80.69% in 2025.
  • The last three reported values for EBT Margin were 80.69% (Q4 2025), 48.59% (Q3 2025), and 25.14% (Q2 2025) per Business Quant data.